गोपनीय: Confidential

## मिसिलस:- 8(39)/2016/डी.पी./एनपीपीए- डीवी-II

### F. No. 8(39)/2016/DP/NPPA-Div. II

कार्यवाहीस. : 171/39/2016/F

Proceeding No : 171/39/2016/F

# Minutes of the 171<sup>st</sup> and 39<sup>th</sup> meeting of Authority under DPCO, 2013 held on 21.12.2016 at 11.00 AM.

- The 171<sup>st</sup> overall meeting of the Authority, which is the 39<sup>th</sup> under the DPCO, 2013 was held on 21<sup>st</sup>, December, 2016 at 11.00 AM under the Chairmanship of Shri Bhupendra Singh, Chairman, NPPA. The following members of the NPPA were present:-
  - (i) Dr. Sharmila Mary Joseph K, Member Secretary, NPPA.
  - (ii) Sh. G.S. Negi, Adviser, Deptt. of Economic Affairs, Ministry of Finance.
  - (iii) Shri Devendra Kumar, Adviser (Cost), Deptt. of Expenditure, Ministry of Finance.
  - (iv) Shri R.Chandrashekhar, Deputy Drug Controller, Deptt. of Health & Family Welfare (representing DCGI).
- 1.1 The following officers of NPPA also attended the meeting and assisted the Authority in its deliberations:-
  - (i) Smt. Roshni Sohni, Director (M&E/Admn.)
  - (ii) Shri A.K. Khurana, Director (Pricing/Ov.)
  - (v) Shri Baljit Singh, Asstt. Director (Pricing)
  - (vi) Shri Prasenjit Das, Asstt. Director (Pricing)
  - 1.2 Chairman, NPPA welcomed all the members present in the meeting especially Sh. G.S. Negi, Adviser, Deptt. of Economic Affairs, Ministry of Finance who was attending the Authority meeting for the first time after his nomination.

#### II. Agenda Items

1. Agenda Item no. 1: Confirmation of Minutes of the 38th Meeting held on 9.11.2016.

The Authority confirmed the minutes of the overall 170<sup>th</sup> and the 38<sup>th</sup> Meeting under DPCO, 2013.

- 2. Agenda Item no. 2: Action Taken Report
- 2.1 Noted.
- 2.2 It was informed that ceiling prices of Paracetamol 80mg suppository, Paracetamol 160mg suppository, Paracetamol 125mg/5ml Oral Liquid and Paracetamol 120mg/5ml Oral Liquid were notified vide S.O. 3430(E) and S.O. 3431(E) dated 10<sup>th</sup> November, 2016, after the ceiling prices of these formulations were approved in the previous 37<sup>th</sup> as well as 38<sup>th</sup> meeting.
- 3. Agenda Item no. 3: Fixation of Ceiling Prices of Scheduled formulations in the revised Schedule-I of DPCO, 2013 (NLEM, 2015).

Shamilayeseple

3.1 The Authority discussed in detail the data and calculation sheets of 54 formulations at the meeting. The Authority approved the ceiling prices in respect of all the following 54 formulations.

S. N O.	UNIQUE NO. AS PER NLEM	NAME OF THE FORMULATION/ COMPOSITIONS	STRENGTH	Dosage From	Unit for Ceiling Price	Propos ed ceiling price under NLEM, 2015
						(Rs.)
1	A. Commo	n Formulations				
·			Section 1-Anesthetic agents	1		
		1.1-	General Anesthetics and oxyge	n		
1	1.1.1	Halothane	Inhalation		Per ML	5.44
2	1.1.8	Thiopentone	Powder for Injection 0.5 g	Injection	Each Pack	37.79
	•	1.3-Preoperative m	edication and sedation for short	term procedu		
3	1.3.3	Midazolam	Injection 5mg/ml	Injection	Per ML	13.46
4	1.3.3	Midazolam	Injection 1mg/ml	Injection	Per ML	5.48
Sec	tion 2-Anal	gesics, antipyretics, nor	steroidal anti inflammatory me	dicines, medic	cines used to	treat gout
-	2.1-	and disease mo	difying agents used in rheumat antipyretics and nonsteroidal ar	nti-inflammato	ry medicines	
5	2.1.2	Diclofenac	Injection 25 mg/ml	Injection	Per ML	1.35
6	2.1.3	Ibuprofen	Oral liquid 100 mg/5 ml	Oral Liquid	Per ML	0.17260
<u> </u>			2.2-Opioid analgesics			
7	2.2.1	Fentanyl	Injection 50mcg/ml	Injection	Per ML	21.06
H			nodifying agents used in rheumato	oid disorders		
			otes and other substances use			
			4.2-Specific			
8	4.2.6	N-acetylcysteine	Injection 200 mg/ml	Injection	Per ML	20.79
		Section	n 5–Anticonvulsants/ Antiepile			180
9	5.3	Diazepam	Oral liquid 2 mg/5 ml	Oral Liquid	Per ML	2.54
10	5.9	Sodium Valporate	200mg/5ml Oral Liquid	Oral Liquid	Per ML	0.54
النا.		Se	ction 6-Anti infective medicines	\$		
			6.2-Antibacterials			
			6.2.1-Beta lactam medicines			
11	6.2.1.2	Amoxicillin (A) + Clavulanic acid (B)	Powder for Injection 500 mg (A) + 100 mg (B)	Injection	Each Pack	83.53
12	6.2.1.3	Ampicillin	Powder for Injection 500 mg	Injection	Each Pack	12.20
.13	6.2.1.4	Benzathine benzylpenicillin	Powder for Injection 12 lac units	Injection	Each Pack	11.27
14	6.2.1.4	Benzathine benzylpenicillin	Powder for Injection 6 lac units	Injection	Each Pack	7.46
$\vdash$			6.2.2-Other antibacterials			
15	6.2.2.1	Azithromycin	Powder for Injection 500 mg	Injection	Each Pack	176.90
16	6.2.2.9	Vancomycin	Powder for Injection 1 gm	Injection	Each Pack	423.48
17	6.2.2.9	Vancomycin	Powder for Injection 500 mg	Injection	Each Pack	254.72
''	0.2.2.8		6.4-Antiviral medicines			
	-			200		

			6.4.1-Antiherpes medicines			
1	8 6.4.1.1	Acyclovir	Oral liquid 400 mg/5 ml	Oral Liquid	Per ML	1 18
	9 6.4.1.1	Acyclovir	Powder for Injection 500 mg	Injection	Each Pack	425.80
2	0 6.4.1.1	Acyclovir	Powder for Injection 250 mg	Injection	Each Pack	329.68
		- Annual - A	6.4.3-Antiretroviral medicines		calife annual control and the Market	
		6.4.3.1-Nu	icleoside reverse transcriptase	Inhibitors		
2	1 6.4.3.1.	3 Lamivudine (A) + Nevirapine (B) + Stavudine (C)	150 mg (A) + 200 mg (B) + 30 mg (C)	Tablet	Per Tablet	14.47
	STATE OF THE STATE OF THE STATE OF	6.4.3.2-Non-	nucleoside reverse transcriptar	se inhibitors		
2	2 6.4.3.2.		Oral Liquid 50mg/5ml	Oral Liquid	Per ML	0.77
	The second line of the second li	Sec	ction 6.5-Antiprotozoal Medicin			
			6.5.3-Antimalarial medicines	THE STATE OF THE S		
			6.5.3.1-For curative treatment			
23	6.5.3.1.7	7 Quinine	Injection 300 mg/ml	Injection	Per ML	9.04
	Se	ction 8 -Antineoplastic/ ir	nmunosuppressives and medic	ines used in p	alliative care	
			8.1-Antineoplastic medicines			
24	8.1.1	5-Fluorouracil	Injection 250 mg/5 ml	Injection	Per ML	2.09
25	8.1.14	Cytosine arabinoside	Powder for Injection 500 mg	Injection	Each Pack	455.72
26	8.1.14	Cytosine arabinoside	Injection 100 mg/ ml	Injection	Each Pack	176.78
27	8.1.19	Etoposide	Injection 20 mg/ml	Injection	Per ML	33.26
28	8.1.27	Methotrexate	Injection 50 mg/ml	Injection	Per ML	35.65
		Sect	ion 12–Cardiovascular medicin	08		
			2.1-Medicines used in angina			
29	12.1.3	Diltiazem	Injection 5 mg/ml	Injection	Per ML	2.92
		12.4-Med	licines used in shock and heart	failure		
30	12.4.2	Dobutamine	Injection 50mg/ml	Injection	Each Pack	34.79
31	12.4.3	Dopamine	Injection 40mg/ml	Injection	Per ML	5.02
		Section	on 20–Gastrointestinal medicin	<b>0</b> 8		
			20.1-Antiulcer medicines			
33	20.1.1	Omeprazole	Capsule 40mg	Capsule	Per Capsule	4.58
	1		20.2-Antiemetics		Capsule	
32	20.2.1	Domperidone	Oral Liquid 1mg/ml	Oral Liquid	Per ML	1.00
_	L	The state of the s	.4-Antispasmodic medicines			
34	20.4.2	Hyoscine butylbromide	Injection 20 mg/ml	Injection	Per ML	9.67
		Section 21-Hormones	s, other endocrine medicines ar	d contracepti	ves	
			21.3-Estrogens			
35	21.3.1	Ethinylestradiol	Tablet 0.05 mg	Tablet	Per Tablet	3.33
		21.4-Mc	edicines used in diabetes melli	us		
		21.4.2-Me	dicines used to treat hypoglyc	emia		
36	21.4.2.1	Glucose	Injection 25 %	Injection	Per ML	0.15953
		Section 23 Muse	le relaxants and cholinesteras	e inhibitors		
		Section 23-Minse				
37	23.1	Atracurium 25-Must	Injection 10 mg/ml	Injection	Each Pack	48.63

Sharmlayseph

,			tion 25-Ophthalmological Medic			
39	25.4.3		-Miotics and antiglaucoma medi		I Per ML	I 11.06
38	23.43	Timolol	Drops 0.5%	Drops	Leim	1 11.00
40	25.5.1	Atropine	25.5-Mydriatics Ointment 1%	LOintment	Per GM	3.36
	20.0.1		tion 26-Oxytocics and Antioxyto		1.0.0	0.00
-			26.1–Oxytocics and abortifacien			protection of the control of the con
41	26.1.2	Methylergometrine		Injection	Per ML	13.24
42	-	Oxytocin	Injection 0.2 mg/ml Injection 5IU/ml	Injection	Per ML	16.37
	1 20.1.0		B-Medicines acting on the respir	1	1,0,100	1 .0.07
		Section 20	28.1–Antiasthmatic medicines	atory tract		
43	28.1.4	Ipratropium		1	Per MDI	0.57
		pratropium	Inhalation (MDI/DPI) 20 mcg/dose		Fel MiDi	0.57
44	28.1.5	Salbutamol	Oral liquid 2 mg/5 ml		Per ML	0.14389
-	.,	S	Section 30–Vitamins and mineral	s	_	
45	30.8	Thiamine	Tablet 100 mg	Tablet	Per Tablet	3.47
	B New For	mulations				
		Section 4-Anti	dotes and other substances use	d in poisoning	9	
	•		4.2-Specific			
46	4.2.6	N-acetylcysteine	Sachet 200 mg	Sachet	Per GM	6.99
			nes, other endocrine medicines a		tives	-
		21.4-	-Medicines used in diabetes mel	litus		
		21.4.1-	Insulins and other antidiabetic a	agents		
47	21.4.1.4	Metformin	Immediate Release 750 mg	Tablet	Per Tablet	2.82
48	21.4.1.4	Metformin	Controlled Release 750 mg	Tablet	Per Tablet	2.23
II		n Formulations				
11	(Explanation	on to Schedule- I) 26.2	Medicines used in pre term lab	our		1
49	26.2.2	Nifedipine	10 mg	Capsule	Per	0.79
_		•		Capsaid	Capsule	0.79
	D. New For	mulations (Explanation	n to Schedule-I)			
Sec	tion 2-Analo	gesics, antipyretics, no	n steroidal anti inflammatory me	edicines, medi	cines used to	treat gout
		and disease mo	odifying agents used in rheumat	oid disorders	•	gou
	2.1-1	Non-opioid analgesics,	antipyretics and nonsteroidal a	nti-inflammato	ory medicines	
50	2.1.4	Mefenamic acid	500 mg	Tablet	Per Tablet	2.27
1	2.1.4	Mefenamic acid	250 mg	Tablet	Per Tablet	1.78
		•	2.2-Opioid analgesics		1	1.70
2	2.2.3	Tramadol	50mg	Tablet	Per Tablet	7.48
		Se	ection 6-Anti infective medicines	s .	, or rapid	7.40
			6.2-Antibacterials			
			6.2.1-Beta lactam medicines			
3	6.2.1.8	Cefixime	400 mg	Capsule	Per	
	J.E. 1.0		-		Capsule	27.13
_		Sect	ion 20–Gastrointestinal medicin	ies		1
			20.1-Antiulcer medicines			
			20.1-Antidicer medicines			

# 4. Agenda Item no. 4: Fixation of retail price in respect of new drugs.

The Authority discussed the following 28 cases of retail price fixation of new drugs falling under the purview of para 2(u) of DPCO, 2013 and approved the retail prices of the following under para 5 of the DPCO 2013, as under:

S. No.	Company name/Product name	Approved Retail Price
4(i)	(1) M/s Aurochem Lab. (I) Pvt. Ltd. (Manufacturer) and M/s Glenmark Pharmaceuticals Ltd. (Marketing company) -Clobetasol Propionate 0.05% w/w, Clotrimazole 1.00% w/w, Neomycin sulphate 0.5% w/w and Chlorocresol (as preservative) 0.10% w/w cream – (Candid 3D Cream).	Gm
4(ii)	M/s Pharma Force Lab. (Manufacturer) and M/s Gem Mankind (Marketing company) - Clobetasol Propionate 0.05% w/w, Clotrimazole 1% w/w, Neomycin Sulphate 0.50% w/w and Chlorocresol (as preservative) 0.10% w/w cream – (Fungikind Cream).	Rs. 3.04 per Gm
4(iii)	M/s SPB Lab. (Manufacturer) and M/s Alkem Lab. Ltd. (Marketing company) – Adaptene 0.1% w/w and Hydrous Benzoyl Peroxide eq. to Benzoyl Peroxide 2.5% w/w – (Oxtiv AP Gel).	Rs. 18.10 per Gm
4(iv)	M/s Cadila Healthcare Ltd. (Manufacturer as well as Marketing company) – Adaplene 0.1% w/w and Hydrous Benzoyl Peroxide eq. to Benzoyl Peroxide 2.5% w/w – (Adapalene and Benzoyl Peroxide Gel).	Rs. 18.10 per Gm
4(v)	M/s Akums Drugs & Pharmaceuticals Ltd. (Manufacturer) and M/s Sun Pharmaceuticals Ind. Ltd. (Marketing company) – Trypsin 48mg, Bromelain 90mg, Rutoside Trihydrate 100mg and Diclofenac Sodium 50mg – (Volitra Enzo Tablet).	Rs. 14.44 per Tablet
4(vi)	M/s Windlas Biotech Ltd. (Manufacturer as well as Marketing company) – Aceclofenac 100mg and Paracetamol 325mg (Aceclofenac & Parcetamol Tablet).	Rs. 2 90 per Tablet
4(vii)	M/s Windlas Biotech Ltd. (Manufacturer as well as Marketing company) – Rabeprazole sodium 20mg and Domperidone SR 30mg– (Rabeprazole sodium & Domperidone SR Capsule).	Rs. 6.87 per Capsule
4(viii)	M/s Windlas Biotech Ltd. (Manufacturer as well as Marketing company) – Pantoprazole sodium 40mg and Domperidone SR 30mg– (Pantoprazole sodium + Domperidone SR Capsule).	Rs. 7.95 per Capsule
4(ix)	M/s Inventia Healthcare P. Ltd. (Manufacturer) and M/s Curatas Pharmaceuticals LLP (Marketing company) – Metformin HCI SR 500mg, Voglibose 0.2mg and Glimepiride 2mg tablet – (Metformin HCI SR, Glimepiride and Voglibose Tablet).	Rs. 90.48 per 10 Tablets
4(x)	M/s Inventia Healthcare P. Ltd. (Manufacturer) and M/s Curatas Pharmaceuticals LLP (Marketing company) – Metformin HCI SR 500mg, Voglibose 0.2mg and Glimepiride 1mg tablet) – (Metformin HCI SR, Glimepiride and Voglibose Tablet).	Rs. 71.43 per 10 Tablets
4(xi)	M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Ajanta Pharma Ltd. (Marketing company) – Metformin HCI (SR) 500mg and Voglibose 0.2mg – (Voglibose + Metformin HCL SR Tablet).	Rs, 4.84 per Tablet
l(xii)		Rs. 3.03 per ML
(xiii)	for irrigation 1000ml.	Rs. 70.83 per 1000ml pack
(xiv)	M/s Infutec Healthcare Ltd. (Manufacturer as well as Marketing company) – Sterile water for irrigation 3000ml.	Rs. 170.38 per 3000ml pack

Marmilangoseghi

4(xv)	M/s Akums Drugs & Pharmaceuticals Ltd. (Manufacturer) and M/s Apex Lab. Pvt. Ltd. (Marketing company) – Mefenamic Acid 50mg and Paracetamol 125mg – (Paracetamol and Mefenamic Acid oral Suspension).	Rs. 0.50 per ML
4(xvi)	M/s Akums Drugs & Pharmaceuticals Ltd. (Manufacturer) and M/s Lupin Ltd. (Marketing company) – Diclofenac sodium 75mg – (Defenac Injection 75mg/1ml).	Rs. 14.30 per ML
4(xvii)	M/s Accent Pharma (Manufacturer) and M/s Blue Cross Lab. Pvt. Ltd. (Marketing company) - Telmisartan 40mg, Hydrochlorothiazide 12.5mg and Amlodipine 5mg (Xstan-AMH Tablets).	Rs. 6.00 per Tablet
4(xviii)	M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Emcure Pharmaceuticals Ltd. (Marketing company) - Rosuvastatin calcium eq. to Rosuvastatin 5mg (as pellets) & Clopidogrel Bisulphate eq. to Clopidogrel 75mg (as pellets) capsule – (Rosuvastatin calcium IP 5mg and Clopidogrel Bisulphate 75mg Capsule).	Rs. 10.35 per Capsule
4(xix)	M/s Synokem Pharmaceuticals Ltd. (Manufacturer) and M/s Erncure Pharmaceuticals Ltd. (Marketing company) - Rosuvastatin calcium eq. to Rosuvastatin 10mg (as pellets) & Clopidogrel Bisulphate eq. to Clopidogrel 75mg (as pellets) capsule – (Rosuvastatin calcium IP 10mg and Clopidogrel Bisulphate 75mg Capsule).	Rs. 13.94 per Capsule
4(xx)	M/s Emcure Pharmaceuticals Ltd. (Manufacturer as well as Marketing company) – Nevirapine 400mg – (Nevirapine extended release tablet).	Rs. 21.22 per Tablet
4(xxi)	M/s Sanzyme (P) Ltd. (Manufacturer) and M/s Sandoz Pvt. Ltd. (Marketing company) - Human Chorionic Gonadotrophin (hcg) 2000 IU, Reconstitue with 1ml of sodium chloride injection (0.9% w/v) – (Chorionic Gonadotrophin Injection).	Rs. 260.80 per vial
4(xxii)	M/s Sanzyme (P) Ltd. (Manufacturer) and M/s Sandoz Pvt. Ltd. (Marketing company) - Human Chorionic: Gonadotrophin (hcg) 10000 IU, Reconstitue with 1ml of sodium chloride injection (0.9% w/v) - (Chorionic Gonadotrophin Injection).	Rs. 550.00 per vial
4(xxiii)	M/s Indu Drugs Pvt. Ltd. (Manufacturer) and M/s Kardian Pharma India Pvt. Ltd. (Marketing company) – Olmesartan Medoxomil 40mg and Hydrochlorothiazide 12.5mg – (Olmetab H Tablet).	Rs. 12.60 per Tablet
4(xxiv)	M/s Indu Drugs Pvt. Ltd. (Manufacturer) and M/s Nutrinova Life Sciences Pvt. Ltd. (Marketing company) - Ferrous Ascorbate 100mg, Folic Acid 1500mcg and Zinc sulphate 22.5mg – (Zyofer XT Tablet).	Rs. 71.17 per 10 Tablets
4(xxv)	M/s Bymaa Lab. Pvt. Ltd. (Manufacturer) and M/s Medo Pharm (Marketing company) - Metformin HCl SR 500mg + Glimepiride 1mg – (Glylim Forte 1 Tablet).	Rs. 4.00 per Tablet
4(xxvi)	M/s Intas Pharmaceuticals Ltd. (Manufacturer as well as Marketing company) – Gemcitabine HCl eq. to Gemcitabine 1.4gm – (Gemcitabine injection 1.4gm).	Rs. 6362.52 per Vial
4(xxvii)	M/s Aristo Lab. Pvt. Ltd. (Manufacturer) and M/s Aristo Pharmaceuticals Pvt. Ltd. (Marketing company) – Ceftriaxone sodium eq. to Ceftriaxone 500mg and Sultactam sodium eq. to Sulbactam 250mg – (Monocef-SB 500mg Injection).	Rs. 69.50 per vial
(xviii)	M/s Bymaa Lab. Pvt. Ltd. (Manufacturer) and M/s Medo Pharm (Marketing company) – Metformin HCl SR 500mg and Voglibose 0.3mg – (Emvose M 0.3 Tablet).	Rs. 57.62 per 10 Tablets

- 5. Agenda Item no. 5: Review order of Department of Pharmaceuticals (DoP) in respect of retail price fixation of Paracetamol 325 mg + Hyoscine Butylbromide 10 mg tablet (Buscogast Plus Tablet) for M/s Boehringer Ingelheim India Pvt. Ltd against S.O. 583 (E) dated 24.02.2016 under DPCO, 2013.
- 5.1 This case was discussed in detail and the Authority approved the revised retail price of Paracetamol 325 mg + Hyoscine Butylbromide 10 mg tablet (Buscogast Plus Tablet) at Rs. 4.32 per tablet.

Stranulayoupt

- 6. Agenda Item no. 6: Review order of Department of Pharmaceuticals (DoP) and Representation from M/s Abbott Healthcare Pvt. Ltd against ceiling price of Ascorbic Acid (Vitamin C) Tablet 500mg notified vide S.O. 1351 (E) dated 02.6.2016.
- 6.1 This case was discussed in detail and the Authority approved the revised ceiling price of Ascorbic Acid (Vitamin C) Tablet 500mg at Rs. 0.84 per tablet
- 7. Agenda Item No. 7: Discontinuation of Clindatime 150 Capsule (Clindamycin) under para 21(2) of DPCO, 2013 by M/s Mankind Pvt. Ltd.
- 7.1 The matter was deferred for the next Authority Meeting.

### Additional agenda items circulated during the meeting:-

- 8. Guidelines regarding discontinuation of scheduled formulations under Para 21(2) of DPCO 2013.
- 8.1 A draft proposal for modified guidelines for discontinuation was circulated to the Authority members. The members were requested to examine and offer their comments by 23<sup>rd</sup> December, 2016 or it will be taken as deemed approved.
- 9. Signing of MOU between NPPA and different web-based Pharma Platforms for dissemination of information on ceiling price of medicines/NPPA mobile app and public grievances
- 9.1 A draft MOU between NPPA and different web-based Pharma Platforms for dissemination of information on ceiling price of medicines/NPPA mobile app and public grievances was circulated to the Authority members. The members were requested to examine and offer their comments by 23<sup>rd</sup> December, 2016 failing which it shall be taken as approved.
- 10. The meeting ended with a vote of thanks to the Chair.

(Dr. Sharmila Mary Joseph K)
Member Secretary